Table 2.
Selected parameters before and after treatment
| Before treatment (n = 19) | After 12 weeks of treatment (n = 19) | p value (Wilcoxon test) | |
|---|---|---|---|
| DAS28(ESR) (for RA; n = 10) | 6.2 (5.5–6.4) | 3.5 (2.8–4.5) | 0.005 |
| BASDAI (for AS; n = 9) | 7.9 (6.6–8.6) | 2.8 (2.0–4.2) | 0.008 |
| ESR (mm/h) | 30 (8–70) | 6 (4–24) | 0.002 |
| WBC (103/l) | 9.3 (8.2–9.9) | 8.0 (6.4–9.7) | 0.015 |
| N/L ratio | 3.0 (2.4–3.6) | 1.4 (1.2–2.1) | <0.001 |
| Serum CRP (mg/l) | 10.24 (4.65–24.31) | 1.52 (0.54–4.13) | 0.010 |
| Serum IL-6 (pg/ml) | 14.23 (5.03–34.61) | 2.32 (1.49–25.14) | 0.044 |
| Salivary CRP (mg/l) | 0.30 (0.02–3.72) | 0.05 (0.00–1.87) | 0.098 |
| Salivary IL-6 (pg/ml) | 1.91 (0.94–2.43) | 1.48 (0.98–2.78) | 0.811 |
Bold values are statistically significant (p < 0.05)
Data presented as the median (interquartile range)
DAS28, 28-joint disease activity score; BASDAI, bath ankylosing spondylitis disease activity Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; N/L ratio, neutrophils to lymphocytes ratio; IL-6, interleukin-6; RA, rheumatoid arthritis; AS, ankylosing spondylitis